Knoww
FDA approves Retatrutide this year?
§ Market context
About this market
Traders currently assign a 98% probability to No on this market. This is the live price of the leading outcome, and it moves as traders buy and sell. Over the past 24 hours, the leading outcome's probability has moved down 1 percentage point. The market has traded approximately $596.23K in volume as of the latest update. It is scheduled to resolve by January 1, 2027.
- Status
- Live trading
- Leading outcome
- No (98%)
- Volume
- $596.23K
- Liquidity
- $1.57K
- Resolution date
- January 1, 2027
- Last updated
- October 23, 2026
Rules and resolution
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Data source and freshness
Odds, volume, and liquidity come from live Polymarket order books. Prices update continuously while trading is open; the figures above reflect the most recent refresh. Probabilities are market prices — what traders collectively pay for a $1 payout if the outcome occurs — not editorial forecasts.
Related markets
Prediction-market prices can move quickly and past probabilities do not guarantee outcomes. Nothing on this page is financial advice.